227 related articles for article (PubMed ID: 25945688)
1. High Risk Retinoblastoma: Prevalence and Success of Treatment in Developing Countries.
ElZomor H; Taha H; Aleieldin A; Nour R; Zaghloul MS; Fawzi M; Kamel A; Alfaar AS
Ophthalmic Genet; 2015; 36(3):287-9. PubMed ID: 25945688
[No Abstract] [Full Text] [Related]
2. Postenucleation adjuvant chemotherapy with vincristine, etoposide, and carboplatin for the treatment of high-risk retinoblastoma.
Kaliki S; Shields CL; Shah SU; Eagle RC; Shields JA; Leahey A
Arch Ophthalmol; 2011 Nov; 129(11):1422-7. PubMed ID: 22084213
[TBL] [Abstract][Full Text] [Related]
3. What is the best treatment for retinoblastoma?
Harbour JW
Am J Ophthalmol; 2004 Sep; 138(3):471-3. PubMed ID: 15364232
[No Abstract] [Full Text] [Related]
4. Retinoma underlying retinoblastoma revealed after tumor response to 1 cycle of chemotherapy.
Dimaras H; Khetan V; Halliday W; Héon E; Chan HS; Gallie BL
Arch Ophthalmol; 2009 Aug; 127(8):1066-8. PubMed ID: 19667353
[No Abstract] [Full Text] [Related]
5. Advanced unilateral retinoblastoma: a case of sparing enucleation treatment failure.
Valente P; De Ioris MA; Romanzo A; Cozza R; Natali G; Buzzonetti L
Can J Ophthalmol; 2016 Apr; 51(2):e40-3. PubMed ID: 27085272
[No Abstract] [Full Text] [Related]
6. Causes of chemoreduction failure in retinoblastoma and analysis of associated factors leading to eventual treatment with external beam radiotherapy and enucleation.
Gündüz K; Günalp I; Yalçindağ N; Unal E; Taçyildiz N; Erden E; Geyik PO
Ophthalmology; 2004 Oct; 111(10):1917-24. PubMed ID: 15465557
[TBL] [Abstract][Full Text] [Related]
7. Histopathologic findings in eyes with retinoblastoma treated only with chemoreduction.
Demirci H; Eagle RC; Shields CL; Shields JA
Arch Ophthalmol; 2003 Aug; 121(8):1125-31. PubMed ID: 12912690
[TBL] [Abstract][Full Text] [Related]
8. MRI findings at baseline and after neoadjuvant chemotherapy in orbital retinoblastoma (IRSS stage III).
Radhakrishnan V; Sharma S; Vishnubhatla S; Bakhshi S
Br J Ophthalmol; 2013 Jan; 97(1):52-8. PubMed ID: 23117972
[TBL] [Abstract][Full Text] [Related]
9. Management of advanced retinoblastoma with intravenous chemotherapy then intra-arterial chemotherapy as alternative to enucleation.
Shields CL; Kaliki S; Al-Dahmash S; Rojanaporn D; Leahey A; Griffin G; Jabbour P; Shields JA
Retina; 2013; 33(10):2103-9. PubMed ID: 23873161
[TBL] [Abstract][Full Text] [Related]
10. Management and outcome of retinoblastoma with vitreous seeds.
Manjandavida FP; Honavar SG; Reddy VA; Khanna R
Ophthalmology; 2014 Feb; 121(2):517-24. PubMed ID: 24572675
[TBL] [Abstract][Full Text] [Related]
11. Practical approach to management of retinoblastoma.
Shields CL; Mashayekhi A; Demirci H; Meadows AT; Shields JA
Arch Ophthalmol; 2004 May; 122(5):729-35. PubMed ID: 15136321
[TBL] [Abstract][Full Text] [Related]
12. Development of new retinoblastomas after 6 cycles of chemoreduction for retinoblastoma in 162 eyes of 106 consecutive patients.
Shields CL; Shelil A; Cater J; Meadows AT; Shields JA
Arch Ophthalmol; 2003 Nov; 121(11):1571-6. PubMed ID: 14609913
[TBL] [Abstract][Full Text] [Related]
13. Risk factors for extraocular relapse following enucleation after failure of chemoreduction in retinoblastoma.
Chantada GL; Dunkel IJ; Antoneli CB; de Dávila MT; Arias V; Beaverson K; Fandiño AC; Chojniak M; Abramson DH
Pediatr Blood Cancer; 2007 Sep; 49(3):256-60. PubMed ID: 17029248
[TBL] [Abstract][Full Text] [Related]
14. Macular retinoblastoma managed with chemoreduction: analysis of tumor control with or without adjuvant thermotherapy in 68 tumors.
Shields CL; Mashayekhi A; Cater J; Shelil A; Ness S; Meadows AT; Shields JA
Arch Ophthalmol; 2005 Jun; 123(6):765-73. PubMed ID: 15955977
[TBL] [Abstract][Full Text] [Related]
15. Orbital fibrosis and intraocular recurrence of retinoblastoma following periocular carboplatin.
Kim JW; Yau JW; Moshfeghi D; Fishman M
J Pediatr Ophthalmol Strabismus; 2010 May; 47 Online():e1-4. PubMed ID: 21214147
[TBL] [Abstract][Full Text] [Related]
16. Chemoreduction for retinoblastoma. Analysis of tumor control and risks for recurrence in 457 tumors.
Shields CL; Mashayekhi A; Cater J; Shelil A; Meadows AT; Shields JA
Am J Ophthalmol; 2004 Sep; 138(3):329-37. PubMed ID: 15364213
[TBL] [Abstract][Full Text] [Related]
17. Uveitis masquerade syndromes: diffuse retinoblastoma in an older child.
All-Ericsson C; Economou MA; Landau I; Träisk F; Seregard S
Acta Ophthalmol Scand; 2007 Aug; 85(5):569-70. PubMed ID: 17655613
[No Abstract] [Full Text] [Related]
18. Residual intraretinal retinoblastoma after chemoreduction failure.
Hwang CK; Aaberg TM; Chevez-Barrios P; Verner-Cole E; Gombos DS; Paysse E; Chintagumpala M; Gao W; Grossniklaus HE
Arch Ophthalmol; 2012 Feb; 130(2):246-8. PubMed ID: 22332223
[No Abstract] [Full Text] [Related]
19. Resolution of iris neovascularization following chemoreduction of advanced retinoblastoma.
Shields CL; Sun H; Manquez ME; Leahey A; Meadows AT; Shields JA
Arch Ophthalmol; 2006 Aug; 124(8):1196-7. PubMed ID: 16908826
[No Abstract] [Full Text] [Related]
20. Factors predictive of recurrence of retinal tumors, vitreous seeds, and subretinal seeds following chemoreduction for retinoblastoma.
Shields CL; Honavar SG; Shields JA; Demirci H; Meadows AT; Naduvilath TJ
Arch Ophthalmol; 2002 Apr; 120(4):460-4. PubMed ID: 11934319
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
